|By Marketwired .||
|March 25, 2014 02:50 PM EDT||
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 03/25/14 -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Monday, March 31, 2014, the Company will file its Annual Report on Form 20-F for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission ("SEC"). The Form 20-F will include audited annual consolidated financial statements, as well as additional information regarding the Company. The Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Tuesday, April 1, 2014 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to provide an update on the Company's business and respond to questions.
Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 19429704. The call is also being webcast, and can be accessed on the investor relations section of the Company's Web site at www.rosettagenomics.com and also at www.streetevents.com.
A telephone replay will be available through April 8, 2014 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 19429704. The webcast will be available for 30 days following the completion of the call.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Mesothelioma Test diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test, 60,000 from the Rosetta Mesothelioma Test, 65,000 from the Rosetta Kidney Cancer Test and 226,000 patients from the Rosetta Lung Cancer Test. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000.
About Rosetta Genomics
Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award. For more information, please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta filing its year-end statements on March 31, 2014, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Jan. 18, 2017 07:30 PM EST Reads: 3,126
Jan. 18, 2017 06:15 PM EST Reads: 4,182
Jan. 18, 2017 05:30 PM EST Reads: 4,859
Jan. 18, 2017 05:00 PM EST Reads: 1,150
Jan. 18, 2017 05:00 PM EST Reads: 224
Jan. 18, 2017 04:45 PM EST Reads: 4,880
Jan. 18, 2017 04:45 PM EST Reads: 5,364
Jan. 18, 2017 04:45 PM EST Reads: 4,564
Jan. 18, 2017 04:30 PM EST Reads: 4,746
Jan. 18, 2017 03:45 PM EST Reads: 4,695
Jan. 18, 2017 03:30 PM EST Reads: 3,678
Jan. 18, 2017 03:30 PM EST Reads: 3,400
Jan. 18, 2017 02:45 PM EST Reads: 1,587
Jan. 18, 2017 02:15 PM EST Reads: 980
Jan. 18, 2017 02:00 PM EST Reads: 393